JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
The CJC-1295 and GHRP-2 blend represents a sophisticated combination of growth hormone-releasing compounds designed for advanced in vitro research applications. CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), functions synergistically with GHRP-2, a hexapeptide growth hormone secretagogue. This dual-component formulation enables researchers to investigate the complex interactions between GHRH and ghrelin receptor pathways in controlled laboratory environments. The lyophilised preparation ensures maximum stability and research-grade purity for precise experimental protocols.
Establish a sterile working environment within a laminar flow hood, ensuring all surfaces are thoroughly decontaminated with appropriate laboratory-grade disinfectants. Allow the lyophilised vial to equilibrate to room temperature for approximately 15-20 minutes before initiating reconstitution procedures. Verify that all reconstitution materials maintain sterile integrity and inspect the lyophilised cake for uniformity and absence of discoloration. Calculate the desired final concentration based on experimental requirements, considering that the total peptide content equals 4mg combined mass.
Prepare the chosen solvent by allowing refrigerated bacteriostatic water to reach room temperature naturally. Avoid rapid temperature changes that may compromise solvent quality or create condensation within the working environment. Organize all materials within easy reach of the sterile field to minimize contamination risks during the reconstitution sequence.
Step 1: Using sterile technique, remove the aluminum cap from the lyophilised vial and thoroughly swab the rubber stopper with 70% isopropanol. Allow the alcohol to evaporate completely before proceeding with needle insertion.
Step 2: Draw the calculated volume of bacteriostatic water into a sterile syringe, ensuring no air bubbles remain in the syringe barrel. Insert the needle through the rubber stopper at a slight angle to prevent coring.
Step 3: Direct the solvent stream toward the vial wall rather than directly onto the lyophilised cake to prevent peptide degradation through mechanical agitation. Inject the solvent slowly and steadily to maintain gentle reconstitution conditions.
Step 4: Withdraw the needle and allow the vial to stand undisturbed for 2-3 minutes, permitting natural dissolution of the peptide matrix. Avoid vigorous shaking or vortexing, which may denature the peptide chains.
Step 5: Gently swirl the vial in circular motions until complete dissolution is achieved. The reconstituted solution should appear clear and colorless without visible particulates or precipitation.
Step 6: If immediate use is not required, transfer appropriate aliquots to sterile amber vials to minimize light exposure and facilitate controlled experimental dosing.
Store reconstituted solutions at 2-8°C in a dedicated laboratory refrigerator, protected from direct light exposure. When using bacteriostatic water, the reconstituted blend maintains stability for up to 28 days under proper refrigerated conditions. Solutions prepared with sterile water require immediate use or division into single-use aliquots for frozen storage at -20°C or below.
Implement a clear labeling system indicating reconstitution date, concentration, and storage requirements. Monitor stored solutions for any signs of precipitation, cloudiness, or color changes that may indicate degradation or contamination.
Element SARMs' CJC-1295 and GHRP-2 blend offers researchers unprecedented opportunities to examine growth hormone pathway modulation in controlled experimental conditions. The reconstituted compound enables investigation of receptor binding kinetics, signal transduction cascades, and downstream metabolic effects in various in vitro model systems. Researchers should establish appropriate control groups and implement rigorous analytical methods to quantify experimental outcomes accurately.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.